12:00 AM
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

XmAb5871: Phase Ib/IIa started

Xencor began a Phase Ib/IIa trial to evaluate twice-weekly doses of XmAb5871 in patients with moderate to severe RA. The trial includes an open-label Phase Ib portion and a double-blind, placebo-controlled Phase...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >